These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34924314)

  • 1. A prospective, multisite implementation-efficacy trial of a collaborative prescriber-pharmacist model of care for Medication Assisted Treatment for Opioid Dependence: Protocol for the EPIC-MATOD study.
    Nielsen S; Cheetham A; Jackson J; Lord S; Petrie D; Jacka D; Picco L; Morgan K
    Res Social Adm Pharm; 2022 Aug; 18(8):3394-3401. PubMed ID: 34924314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informing a collaborative-care model for delivering medication assisted treatment for opioid dependence (MATOD): An analysis of pharmacist, prescriber and patient perceptions.
    Cheetham A; Morgan K; Jackson J; Lord S; Nielsen S
    Res Social Adm Pharm; 2023 Mar; 19(3):526-534. PubMed ID: 36216753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Before the training I just assumed they've done something bad": Reporting on professional training for pharmacy assistants and pharmacy dispensary technicians on medically assisted treatment of opioid dependence.
    Patil T; Mummery J; Salman M; Cooper S; Williams D
    Res Social Adm Pharm; 2021 Jul; 17(7):1250-1258. PubMed ID: 33004304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
    Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
    Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.
    Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M;
    BMJ Open; 2020 Jul; 10(7):e034389. PubMed ID: 32737087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the role of community pharmacies in current medication for opioid use disorder care practices.
    Comanici KH; Nichols MA; Scott C; Conklin M; Ott CA; Arnett S; Karwa R
    J Am Pharm Assoc (2003); 2023; 63(1):261-268.e2. PubMed ID: 36209034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol.
    Bryan MA; Smid MC; Cheng M; Fortenberry KT; Kenney A; Muniyappa B; Pendergrass D; Gordon AJ; Cochran G
    Addict Sci Clin Pract; 2020 Oct; 15(1):33. PubMed ID: 33129355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploration of the role of pharmacists within general practice clinics: the protocol for the pharmacists in practice study (PIPS).
    Tan E; Stewart K; Elliott RA; George J
    BMC Health Serv Res; 2012 Aug; 12():246. PubMed ID: 22876813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.
    Cochran G; Cole ES; Warwick J; Donohue JM; Gordon AJ; Gellad WF; Bear T; Kelley D; DiDomenico E; Pringle J
    Addict Sci Clin Pract; 2019 Aug; 14(1):25. PubMed ID: 31366408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.
    Winstock AR; Lea T; Sheridan J
    Addiction; 2010 Feb; 105(2):335-42. PubMed ID: 20078490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing implementation facilitation of a primary care-based collaborative care clinical program using a hybrid type III interrupted time series design: a study protocol.
    Midboe AM; Martino S; Krein SL; Frank JW; Painter JT; Chandler M; Schroeder A; Fenton BT; Troszak L; Erhardt T; Kerns RD; Becker WC
    Implement Sci; 2018 Nov; 13(1):145. PubMed ID: 30486877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
    DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
    Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Collaborative Protocolized Approach by Community Pharmacists and General Medical Practitioners for an Australian Minor Ailments Scheme: Protocol for a Cluster Randomized Controlled Trial.
    Dineen-Griffin S; Garcia-Cardenas V; Rogers K; Williams K; Benrimoj SI
    JMIR Res Protoc; 2019 Aug; 8(8):e13973. PubMed ID: 31400107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
    BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing and evaluating physician-pharmacist collaborative clinics to manage patients with type 2 diabetes in primary hospitals in Hunan province: study protocol of a multi-site randomized controlled trial in the era of COVID-19 pandemic.
    Tan SL; Xiao J; Yuan HY; Chen L; Wang Q; Xiang DX; Li X; Zhou YG; Guo Y; Huang HY; Zhao DH; Li Y; Wang L; Li Q; Liu J; Xu P
    BMC Health Serv Res; 2022 Mar; 22(1):299. PubMed ID: 35246117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
    Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
    Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.